Carbidopa

• CAS: 38821-49-7
• Catalog Number: ACM38821497
• Category: Other Products
• Molecular Weight: 244.24
• Molecular Formula: C₁₀H₁₆N₂O₅
• Synonyms: (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamicacidmonohydrat;(-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-hydrocinnamicacimonohydr;alpha-hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoicacimonohydra;lodosyn;CARBIDOPA;CARBIDOPA HYDRATE;CARBIDOPA MONOHYDRATE;(S)-(-)-CARBIDOPA MONOHYDRATE
• Supplemental Hazard Statements: H319
• Symbol: GHS07

Custom Q&A

What is the chemical formula of Carbidopa?

The chemical formula of Carbidopa is C10H14N2O4.

What is the molecular weight of Carbidopa?

The molecular weight of Carbidopa is 226.23 g/mol.

How does Carbidopa prevent the conversion of levodopa to dopamine?

Carbidopa is a dopa decarboxylase inhibitor, which prevents the conversion of levodopa to dopamine.

What is the role of Carbidopa as?

Carbidopa acts as an EC 4.1.1.28 inhibitor, an antiparkinson drug, and a dopaminergic agent.

What is the chemical name of Carbidopa?

The chemical name of Carbidopa is N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate.

Why is Carbidopa always administered concomitantly with levodopa?

Carbidopa is always administered with levodopa because it potently inhibits aromatic amino acid decarboxylase and does not cross the blood-brain barrier.

Does Carbidopa penetrate the blood-brain barrier?

No, Carbidopa does not penetrate the blood-brain barrier.

Why is Carbidopa used as an adjunct with levodopa?

Carbidopa is used as an adjunct with levodopa to prevent levodopa degradation to dopamine in extracerebral tissue, decreasing the peripheral side effects of levodopa.

What is the IUPAC name of Carbidopa?

The IUPAC name of Carbidopa is (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid.

When was the first approved product containing only Carbidopa developed?

The first approved product containing only Carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved in 2014.

Synthetic Use

Upstream Synthesis Route 1

• 37178-37-3

• 38821-49-7

Reference: [1]Current Patent Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD. - US2003/147957, 2003, A1

Upstream Synthesis Route 2

• 1426847-87-1

• 38821-49-7

Reference: [1]Pericas, Lex; Shafir, Alexandr; Vallribera, Adelina
[Organic Letters, 2013, vol. 15, # 7, p. 1448 - 1451]